MX358472B - Vector de expresion de receptor de antigeno quimerico (car) y celulas t que expresan car. - Google Patents
Vector de expresion de receptor de antigeno quimerico (car) y celulas t que expresan car.Info
- Publication number
- MX358472B MX358472B MX2017004393A MX2017004393A MX358472B MX 358472 B MX358472 B MX 358472B MX 2017004393 A MX2017004393 A MX 2017004393A MX 2017004393 A MX2017004393 A MX 2017004393A MX 358472 B MX358472 B MX 358472B
- Authority
- MX
- Mexico
- Prior art keywords
- car
- codes
- nucleic acid
- expressing
- cells
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 7
- 239000013604 expression vector Substances 0.000 title abstract 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 9
- 150000007523 nucleic acids Chemical class 0.000 abstract 7
- 102000039446 nucleic acids Human genes 0.000 abstract 7
- 108020004707 nucleic acids Proteins 0.000 abstract 7
- 230000036737 immune function Effects 0.000 abstract 3
- 230000001737 promoting effect Effects 0.000 abstract 3
- 102100036842 C-C motif chemokine 19 Human genes 0.000 abstract 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 abstract 1
- 102000000704 Interleukin-7 Human genes 0.000 abstract 1
- 108010002586 Interleukin-7 Proteins 0.000 abstract 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 abstract 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 abstract 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 abstract 1
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229940100994 interleukin-7 Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/46444—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/464442—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5418—IL-7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
La presente invención se refiere a proporcionar células T que expresan CAR que co-expresan un receptor de antígeno quimérico (CAR) y un factor mejorador de la función inmune de células T y tienen un alto efecto de inducción de inmunidad y actividad antitumor, y proporcionar un vector para la expresión de CAR para la preparación de las células T que expresan CAR; un vector de expresión de CAR comprende un ácido nucleico que codifica un receptor de antígeno quimérico (CAR) y un ácido nucleico que codifica un factor mejorador de la función inmune de células T, en donde el ácido nucleico que codifica un factor mejorador de la función inmune es un ácido nucleico que codifica interleucina-7 y se prepara un ácido nucleico que codifica CCL19, un ácido nucleico que codifica un mutante negativo dominante de SHP-1, o un ácido nucleico que codifica un mutante negativo dominante de SHP-2, o células T que expresan CAR introducidas con el vector de expresión de CAR. Figura 2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014208200 | 2014-10-09 | ||
PCT/JP2015/005080 WO2016056228A1 (ja) | 2014-10-09 | 2015-10-06 | Car発現ベクター及びcar発現t細胞 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2017004393A MX2017004393A (es) | 2017-06-22 |
MX358472B true MX358472B (es) | 2018-08-21 |
Family
ID=55652864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017004393A MX358472B (es) | 2014-10-09 | 2015-10-06 | Vector de expresion de receptor de antigeno quimerico (car) y celulas t que expresan car. |
Country Status (28)
Country | Link |
---|---|
US (3) | US10316102B2 (es) |
EP (2) | EP3205720B1 (es) |
JP (5) | JP6161098B2 (es) |
KR (1) | KR101890638B1 (es) |
CN (1) | CN107109421B (es) |
AU (1) | AU2015329444B2 (es) |
BR (1) | BR112017006710B1 (es) |
CA (1) | CA2962375C (es) |
CY (1) | CY1122324T1 (es) |
DK (2) | DK3597742T3 (es) |
ES (2) | ES2927366T3 (es) |
HR (2) | HRP20221211T1 (es) |
HU (2) | HUE060047T2 (es) |
IL (1) | IL251504B (es) |
LT (2) | LT3205720T (es) |
MX (1) | MX358472B (es) |
MY (1) | MY167722A (es) |
NZ (1) | NZ730382A (es) |
PH (1) | PH12017500596B1 (es) |
PL (2) | PL3597742T3 (es) |
PT (2) | PT3205720T (es) |
RS (2) | RS63601B1 (es) |
RU (1) | RU2670147C1 (es) |
SG (1) | SG11201702391RA (es) |
SI (2) | SI3205720T1 (es) |
TW (1) | TWI688651B (es) |
WO (1) | WO2016056228A1 (es) |
ZA (1) | ZA201701968B (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2927366T3 (es) | 2014-10-09 | 2022-11-04 | Univ Yamaguchi | Vector de expresión de CAR y células T que expresan CAR |
GB201509413D0 (en) * | 2015-06-01 | 2015-07-15 | Ucl Business Plc | Fusion protein |
JP2019508036A (ja) | 2016-02-16 | 2019-03-28 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 免疫療法組成物及び方法 |
MX2018010974A (es) * | 2016-03-17 | 2019-03-28 | Univ Yamaguchi | Célula inmunocompetente y vector de expresión que expresa factores reguladores de la función inmune. |
US11447562B2 (en) * | 2017-01-01 | 2022-09-20 | Chi-Yu Gregory Lee | RP215 chimeric antigen receptor construct and methods of making and using same |
IL300270A (en) * | 2017-01-10 | 2023-04-01 | Univ Yamaguchi | Anti-GPC3 antibody |
BR112019019941B1 (pt) * | 2017-03-27 | 2023-12-05 | Noile-Immune Biotech, Inc | Polinucleotídeo compreendendo uma sequência de base que codifica o receptor de antígeno quimérico, vetor e método |
CN108484777B (zh) * | 2017-03-31 | 2022-07-12 | 李吉祐 | 人源化rp215单克隆抗体的嵌合抗原受体构建体及核酸分子与应用 |
CN111163758A (zh) * | 2017-10-10 | 2020-05-15 | 国立大学法人山口大学 | 具有记忆功能的t细胞或b细胞的增强剂、恶性肿瘤复发抑制剂、以及对t细胞或b细胞诱导记忆功能的诱导剂 |
IL275453B1 (en) * | 2017-12-24 | 2024-02-01 | Noile Immune Biotech Inc | An immunocompetent cell expressing a cell surface compound that specifically recognizes human mesothelin, IL-7, and CCL19 |
WO2019131770A1 (ja) * | 2017-12-27 | 2019-07-04 | 武田薬品工業株式会社 | 核酸含有脂質ナノ粒子及びその用途 |
CN108641000A (zh) * | 2018-04-26 | 2018-10-12 | 上海怡豪生物科技有限公司 | 肝癌的双靶点car-t治疗载体及其构建方法和应用 |
CN108659133A (zh) * | 2018-04-26 | 2018-10-16 | 上海怡豪生物科技有限公司 | 肺癌的双靶点car-t治疗载体及其构建方法和应用 |
CN108641001A (zh) * | 2018-04-26 | 2018-10-12 | 上海怡豪生物科技有限公司 | 结肠癌的双靶点car-t治疗载体及其构建方法和应用 |
AU2019271819A1 (en) * | 2018-05-15 | 2021-01-14 | Crage Medical Co., Limited | Genetically engineered cell and application thereof |
KR20190141511A (ko) * | 2018-06-14 | 2019-12-24 | 주식회사 녹십자랩셀 | 신규 펩티드, 이를 포함하는 키메라 항원 수용체 및 이를 발현하는 면역 세포 |
CN108866004A (zh) * | 2018-06-26 | 2018-11-23 | 奥妙生物技术(广州)有限公司 | Shp-1敲除的t细胞及其构建方法 |
CN112469829B (zh) * | 2018-07-17 | 2023-07-07 | 诺伊尔免疫生物科技株式会社 | 包含抗gpc3单链抗体的car |
CN109055430A (zh) * | 2018-08-14 | 2018-12-21 | 杭州荣泽生物科技有限公司 | 一种共表达il18和ccl19蛋白及靶向muc1基因car-t细胞的制备方法 |
KR20210053925A (ko) * | 2018-08-31 | 2021-05-12 | 노일 이뮨 바이오테크 가부시키가이샤 | Car 발현 t 세포 및 car 발현 벡터 |
CN112771167A (zh) * | 2018-09-20 | 2021-05-07 | 科济生物医药(上海)有限公司 | 表达有趋化因子的细胞及用途 |
CN113286874A (zh) * | 2018-10-12 | 2021-08-20 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(CARs)组合物及使用方法 |
CN109504660B (zh) * | 2018-11-02 | 2021-08-06 | 温州启星生物技术有限公司 | 一种***car-t细胞及其构建方法和应用 |
WO2020106621A1 (en) * | 2018-11-19 | 2020-05-28 | Board Of Regents, The University Of Texas System | A modular, polycistronic vector for car and tcr transduction |
WO2020183131A1 (en) * | 2019-03-08 | 2020-09-17 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
CN112080525A (zh) * | 2019-06-14 | 2020-12-15 | 南京艾德免疫治疗研究院有限公司 | 一种改良型嵌合抗原受体t细胞的制备 |
CN112080526A (zh) * | 2019-06-14 | 2020-12-15 | 南京艾德免疫治疗研究院有限公司 | 表达il-7和car的表达载体及免疫细胞 |
JP2021016371A (ja) * | 2019-07-23 | 2021-02-15 | 株式会社東芝 | Car−t細胞の製造方法、核酸導入キャリア及びキット |
KR20220092543A (ko) | 2019-10-28 | 2022-07-01 | 노일 이뮨 바이오테크 가부시키가이샤 | 암의 치료를 위한 의약, 조합 의약, 의약 조성물, 면역 응답성 세포, 핵산 전달 비히클 및 제품 |
CN110922490B (zh) * | 2019-12-05 | 2023-03-03 | 浙江启新生物技术有限公司 | 分泌白介素7和趋化因子21的car表达载体及应用 |
JP2023513752A (ja) * | 2020-02-14 | 2023-04-03 | ベイジン ヨンタイ ルイケ バイオテクノロジー カンパニー リミテッド | 外部から導入された細胞シグナル伝達調節因子を過剰発現する免疫細胞及びその使用 |
CN113528483A (zh) * | 2020-04-22 | 2021-10-22 | 复星凯特生物科技有限公司 | Shp2特异性失活突变蛋白及其在car-t治疗中应用 |
GB202006820D0 (en) * | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
US20230257705A1 (en) | 2020-06-17 | 2023-08-17 | Kyoto University | Chimeric antigen receptor-expressing immunocompetent cells |
KR102297396B1 (ko) | 2020-07-29 | 2021-09-06 | (주)티카로스 | 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포 |
JP2023553157A (ja) | 2020-12-10 | 2023-12-20 | ユーティレックス カンパニー リミテッド | 抗-pd-1抗体およびその用途 |
WO2022135357A1 (en) * | 2020-12-22 | 2022-06-30 | Sunshine Lake Pharma Co., Ltd. | A hIL7/hCCL19 DOUBLE GENE RECOMBINANT ONCOLYTIC VIRUS AND ITS PREPARATION METHOD AND USE |
CN114716548A (zh) | 2021-01-05 | 2022-07-08 | (株)爱恩德生物 | 抗-fgfr3抗体及其用途 |
CN112961248B (zh) * | 2021-02-22 | 2022-03-18 | 广州百暨基因科技有限公司 | 共表达IL-7和CCR2b的嵌合抗原受体融合蛋白及其应用 |
WO2022245098A1 (ko) | 2021-05-18 | 2022-11-24 | 주식회사 바이오솔루션 | 세포외소포체 분비능이 증진된 면역세포 및 이를 활용한 면역 항암요법 |
CN117642421A (zh) * | 2021-07-29 | 2024-03-01 | 武田药品工业株式会社 | 特异性靶向间皮素的工程化免疫细胞以及其用途 |
CN113913385A (zh) * | 2021-09-01 | 2022-01-11 | 苏州璞惠卓越生物科技有限公司 | 一种抑制蛋白阻断型嵌合抗原受体修饰的免疫细胞及其用途 |
CN113921082B (zh) * | 2021-10-27 | 2023-04-07 | 云舟生物科技(广州)股份有限公司 | 基因搜索权重调整方法、计算机存储介质及电子设备 |
WO2023081455A2 (en) * | 2021-11-08 | 2023-05-11 | Memorial Sloan-Kettering Cancer Center | Immune cells expressing glucose transporter 5 (gluts) and compositions and methods including the same |
WO2023223292A1 (en) * | 2022-05-20 | 2023-11-23 | Takeda Pharmaceutical Company Limited | Methods of producing engineered immune cells |
CN115505601A (zh) * | 2022-10-17 | 2022-12-23 | 深圳市先康达生命科学有限公司 | 一种两级SynNotch逻辑调控结构及其应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5857318A (ja) * | 1981-10-01 | 1983-04-05 | Nippon Koutai Kenkyusho:Kk | 癌細胞障害性リンパ球の製造法 |
JP5312721B2 (ja) | 2000-11-07 | 2013-10-09 | シティ・オブ・ホープ | Cd19特異的再指向免疫細胞 |
KR20050118057A (ko) * | 2004-04-24 | 2005-12-15 | 김상희 | 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품 |
TWI436775B (zh) * | 2007-08-24 | 2014-05-11 | Oncotherapy Science Inc | 以抗原胜肽合併化療藥劑治療胰臟癌 |
CA2739902A1 (en) * | 2008-10-08 | 2010-04-15 | Intrexon Corporation | Engineered cells expressing multiple immunomodulators and uses thereof |
KR102062407B1 (ko) | 2010-12-09 | 2020-01-03 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도 |
AU2011343887B2 (en) | 2010-12-14 | 2016-06-16 | University Of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer |
EP2694549B1 (en) | 2011-04-08 | 2018-08-15 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
EP3692794A1 (en) * | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
EP2765193B1 (en) | 2011-10-07 | 2017-08-09 | Mie University | Chimeric antigen receptor |
ES2774160T3 (es) * | 2012-02-13 | 2020-07-17 | Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute | Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos |
JP2015509716A (ja) * | 2012-02-22 | 2015-04-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 第二世代キメラ抗原受容体におけるcd2シグナル伝達ドメインの使用 |
CN102625373A (zh) * | 2012-02-22 | 2012-08-01 | 中兴通讯股份有限公司 | 一种智能载波管理方法及装置 |
ES2927366T3 (es) * | 2014-10-09 | 2022-11-04 | Univ Yamaguchi | Vector de expresión de CAR y células T que expresan CAR |
-
2015
- 2015-10-06 ES ES19196196T patent/ES2927366T3/es active Active
- 2015-10-06 LT LT15849416T patent/LT3205720T/lt unknown
- 2015-10-06 HU HUE19196196A patent/HUE060047T2/hu unknown
- 2015-10-06 PL PL19196196.0T patent/PL3597742T3/pl unknown
- 2015-10-06 CA CA2962375A patent/CA2962375C/en active Active
- 2015-10-06 AU AU2015329444A patent/AU2015329444B2/en active Active
- 2015-10-06 HU HUE15849416A patent/HUE046710T2/hu unknown
- 2015-10-06 CN CN201580053922.1A patent/CN107109421B/zh active Active
- 2015-10-06 MY MYPI2017701137A patent/MY167722A/en unknown
- 2015-10-06 SI SI201530950T patent/SI3205720T1/sl unknown
- 2015-10-06 RU RU2017114545A patent/RU2670147C1/ru active
- 2015-10-06 RS RS20220895A patent/RS63601B1/sr unknown
- 2015-10-06 EP EP15849416.1A patent/EP3205720B1/en active Active
- 2015-10-06 NZ NZ730382A patent/NZ730382A/en unknown
- 2015-10-06 WO PCT/JP2015/005080 patent/WO2016056228A1/ja active Application Filing
- 2015-10-06 PL PL15849416T patent/PL3205720T3/pl unknown
- 2015-10-06 BR BR112017006710A patent/BR112017006710B1/pt active IP Right Grant
- 2015-10-06 PT PT158494161T patent/PT3205720T/pt unknown
- 2015-10-06 JP JP2016552830A patent/JP6161098B2/ja active Active
- 2015-10-06 DK DK19196196.0T patent/DK3597742T3/da active
- 2015-10-06 RS RSP20191315 patent/RS59441B1/sr unknown
- 2015-10-06 US US15/513,870 patent/US10316102B2/en active Active
- 2015-10-06 EP EP19196196.0A patent/EP3597742B1/en active Active
- 2015-10-06 SG SG11201702391RA patent/SG11201702391RA/en unknown
- 2015-10-06 ES ES15849416T patent/ES2751945T3/es active Active
- 2015-10-06 PT PT191961960T patent/PT3597742T/pt unknown
- 2015-10-06 KR KR1020177009895A patent/KR101890638B1/ko active IP Right Grant
- 2015-10-06 SI SI201531887T patent/SI3597742T1/sl unknown
- 2015-10-06 DK DK15849416.1T patent/DK3205720T3/da active
- 2015-10-06 HR HRP20221211TT patent/HRP20221211T1/hr unknown
- 2015-10-06 LT LTEP19196196.0T patent/LT3597742T/lt unknown
- 2015-10-06 MX MX2017004393A patent/MX358472B/es active IP Right Grant
- 2015-10-08 TW TW104133272A patent/TWI688651B/zh active
-
2017
- 2017-03-22 ZA ZA2017/01968A patent/ZA201701968B/en unknown
- 2017-03-31 PH PH12017500596A patent/PH12017500596B1/en unknown
- 2017-04-02 IL IL251504A patent/IL251504B/en active IP Right Grant
- 2017-06-06 JP JP2017111736A patent/JP6683990B2/ja active Active
-
2019
- 2019-05-06 US US16/404,165 patent/US10906984B2/en active Active
- 2019-10-11 HR HRP20191839TT patent/HRP20191839T1/hr unknown
- 2019-11-26 CY CY20191101239T patent/CY1122324T1/el unknown
-
2020
- 2020-03-19 JP JP2020048623A patent/JP7008350B2/ja active Active
- 2020-12-23 US US17/133,286 patent/US20210253726A1/en active Pending
-
2021
- 2021-12-28 JP JP2021213604A patent/JP7300763B2/ja active Active
-
2023
- 2023-06-13 JP JP2023097065A patent/JP2023116674A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500596A1 (en) | Car expression vector and car-expressing t cells | |
CY1125032T1 (el) | Υποκινητης mnd χιμαιρικους υποδοχεις αντιγονου | |
EP4036109A3 (en) | Methods of making chimeric antigen receptor-expressing cells | |
MX2022000132A (es) | Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t. | |
MX2018010733A (es) | Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas. | |
EP4234685A3 (en) | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells | |
MX2019003489A (es) | Moleculas del receptor de envolvimiento quimerico. | |
MX2021007011A (es) | Receptores de antigenos quimericos de antigeno de maduracion de celulas b. | |
WO2015112626A8 (en) | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules | |
PH12017501044A1 (en) | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof | |
MX2019002946A (es) | Anticuerpos anti-pd-1 y sus usos. | |
MX2016012713A (es) | Inmunoreceptores especificos de claudina-6 y epitopos de celulas t. | |
WO2017015427A8 (en) | Methods for improving the efficacy and expansion of immune cells | |
PH12017500861A1 (en) | Anti-interleukin-33 antibodies and uses thereof | |
AU2018397910A1 (en) | Nucleic acid-containing lipid nano-particle and use thereof | |
MX2017001079A (es) | Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma). | |
MX2020007266A (es) | Moleculas del receptor quimerico de engullido y metodos de uso. | |
MX2016009965A (es) | Produccion de alta titulacion de vectores virales adenoasociados. | |
MX2017003478A (es) | Anticuerpos anti-fgfr2/3 y metodos para su uso. | |
EP4310097A3 (en) | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof | |
BR112014024893A2 (pt) | receptores de antígenos quiméricos direcionados a antígeno de maturação de célula b | |
EP3329282A4 (en) | QUALITY OF IMMUNOLOGICAL SYNAPSE AS THE PREDICTOR OF THE EFFECTIVENESS OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS | |
ZA201800804B (en) | Novel anti-human gpvi antibodies and uses thereof | |
EP4295914A3 (en) | Genetically-engineered drug resistant t cells and methods of using the same | |
NZ721832A (en) | Solid forms of tenofovir |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |